Retraction: The Epstein - Barr Virus - encoded miR - BART22 targets MAP3K5 to promote host cell proliferative and invasive abilities
in nasopharyngeal carcinoma Ruichao Chen, Minfeng Zhang, Qiulian Li, Hanzhen Xiong, Shaoyan Liu, Weiyi Fang, Qianbing Zhang, Zhen Liu, Xuehu Xu, Qingping Jiang Journal of Cancer 2017; 8:3130 - 3130
Zoledronic acid reverses cisplatin resistance
in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway.
Not exact matches
In certain individuals, however, EBV has been linked to various cancers, including African Burkitt lymphoma, Hodgkin's disease,
nasopharyngeal carcinoma, gastric adenocarcinoma, and leiomyosarcoma.
14255: STAT3 Signaling During Chemo - Radiation for Squamous Cell
Carcinoma of the Head and Neck 14340: A Phase II, Randomized, Open - Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736
in Combination with Tremelimumab
in Patients with Recurrent or Metastatic Squamous Cell
Carcinoma of the Head and Neck (SCCHN) 14258: Randomized Phase II and Phase III Studies of Individualized Treatment for
Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
These SNPs can result
in altered levels of expression of some miRNAs from the BART variant frequently present
in Chinese and Indonesian
nasopharyngeal carcinoma (NPC) samples.